Keyphrases
Vascular Endothelial Growth Factor
100%
Chemical Proteomics
100%
Kinase Inhibition
100%
Affinity Probe
100%
Vascular Endothelial Growth Factor Receptor (VEGFR)
100%
Probe Targeting
100%
Selectivity Profile
100%
Small Molecules
40%
Kinase Inhibitor
40%
Recent Advances
20%
Physiological Condition
20%
Clinical Application
20%
Therapeutic Potential
20%
Cancer Treatment
20%
Mechanism of Action
20%
Therapeutic Strategies
20%
Mass Spectrometry
20%
Drug-target Interaction
20%
Drug Molecules
20%
Competitive Binding Assay
20%
Lysate
20%
Solid Tumors
20%
Protein Kinase
20%
Risk Potential
20%
Neoangiogenesis
20%
Target Selectivity
20%
Cancer Cell Lines
20%
C-kit
20%
Chemical Tools
20%
Receptor Antagonist
20%
Human Placenta
20%
Platelet-derived Growth Factor Receptor (PDGFR)
20%
PDGFR Inhibitor
20%
Axitinib
20%
Pazopanib
20%
Kinobeads
20%
Drug Analysis
20%
Placenta Tissue
20%
New Probes
20%
Binding Spectra
20%
Biochemistry, Genetics and Molecular Biology
Phosphotransferase
100%
Kinase
100%
Vascular Endothelial Growth Factor
100%
VEGF Receptors
100%
Proteomics
100%
Small Molecule
40%
Cell Lysate
20%
Neoangiogenesis
20%
Cancer Cell
20%
Mass Spectrometry
20%
Binding Competition
20%
Protein Kinases
20%
Tissue Plasminogen Activator
20%
Axitinib
20%
Pazopanib
20%
Medicine and Dentistry
Vasculotropin
100%
Receptor
100%
Phosphotransferase Inhibitor
100%
Vasculotropin Receptor
100%
Proteomics
100%
Mass Spectrum
20%
Cancer Therapy
20%
Solid Malignant Neoplasm
20%
Cancer Cell Line
20%
Competitive Binding Assay
20%
Tissue Plasminogen Activator
20%
Pazopanib
20%
Axitinib
20%
Placenta Tissue
20%
Protein Kinases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
100%
Receptor
100%
Phosphotransferase Inhibitor
100%
Vasculotropin Receptor
100%
Malignant Neoplasm
40%
Axitinib
20%
Solid Malignant Neoplasm
20%
Pazopanib
20%
Protein Kinases
20%
Tissue Plasminogen Activator
20%
Chemistry
Vascular Endothelial Growth Factor
100%
Phosphotransferase Inhibitor
100%
Proteomics
100%
Mass Spectrometry
16%
Drug Target
16%
Axitinib
16%
Pazopanib
16%